Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1998 2
2002 1
2005 2
2006 1
2007 1
2008 3
2009 1
2010 3
2012 1
2013 1
2016 1
2017 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ?term=lewczuk j
Your search for ?term=Lewczuc J retrieved no results
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. ...
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of ed …
Oral rivaroxaban for symptomatic venous thromboembolism.
EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. EINSTEIN Investigators, et al. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3. N Engl J Med. 2010. PMID: 21128814 Free article. Clinical Trial.
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. ...
CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that ma …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators. Ghofrani HA, et al. Lancet Respir Med. 2024 Apr;12(4):e21-e30. doi: 10.1016/S2213-2600(24)00027-4. Lancet Respir Med. 2024. PMID: 38548406 Clinical Trial.
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. ...
BACKGROUND: Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thr …
[Hypoxemia in pulmonary embolism--the occurrence, patomechanism and significance].
Lewczuk J, Drozdz D. Lewczuk J, et al. Pol Merkur Lekarski. 2008 Jan;24(139):42-4. Pol Merkur Lekarski. 2008. PMID: 18634252 Review. Polish.
H in massive APE requires oxygen therapy, and it can be speculated, whether long term oxygenation should be added to the anticoagulation in nonoperated, hypoxemic patients with CTEPH....
H in massive APE requires oxygen therapy, and it can be speculated, whether long term oxygenation should be added to the anticoagulat …
Importance of cardiac biomarkers in risk stratification in acute pulmonary embolism.
Mikulewicz M, Lewczuk J. Mikulewicz M, et al. Among authors: lewczuk j. Cardiol J. 2008;15(1):17-20. Cardiol J. 2008. PMID: 18651380 Free article. Review.
The principal aim of ongoing studies is to find patients with hemodynamically stable APE who can be candidates for thrombolytic therapy. The usefulness of biomarkers in long-term prognosis and their value to identify APE patients in whom chronic thromboembolic pulmonary hy …
The principal aim of ongoing studies is to find patients with hemodynamically stable APE who can be candidates for thrombolytic therapy. The …
[Combined pulmonary fibrosis and emphysema - case report and literature review].
Kosacka M, Brzecka A, Jankowska R, Lewczuk J, Mroczek E, Weryńska B. Kosacka M, et al. Among authors: lewczuk j. Pneumonol Alergol Pol. 2009;77(2):205-10. Pneumonol Alergol Pol. 2009. PMID: 19462358 Free article. Review. Polish.
Severe pulmonary hypertension (SPAP 80 mm Hg) was confirmed by echocardiography and right cardiac catherisation. The patient received long-term oxygen therapy, inhaled corticosteroid and Ca-blocker....
Severe pulmonary hypertension (SPAP 80 mm Hg) was confirmed by echocardiography and right cardiac catherisation. The patient received long- …
Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.
Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jaïs X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G. Delcroix M, et al. Among authors: lewczuk j. Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29. Circulation. 2016. PMID: 26826181
A European registry was set up in 27 centers to evaluate long-term outcome and outcome correlates in 2 distinct populations of operated and not-operated patients who have chronic thromboembolic pulmonary hypertension. ...Additional correlates of mortality were bridging the …
A European registry was set up in 27 centers to evaluate long-term outcome and outcome correlates in 2 distinct populations of operat …
[Dysfunction of coagulation processes in patients after acute coronary syndrome--therapeutic implications].
Kaczmarzyk-Radka A, Lenartowska L, Lewczuk J. Kaczmarzyk-Radka A, et al. Among authors: lewczuk j. Pol Merkur Lekarski. 2010 Apr;28(166):293-6. Pol Merkur Lekarski. 2010. PMID: 20491340 Review. Polish.
However, many patients after ACS experience major adverse cardiovascular events (MACE) despite optimal long term antiplatelet therapy. The possible reasons seem to be not only the resistance to this drugs but also underestimated coagulation processes. ...
However, many patients after ACS experience major adverse cardiovascular events (MACE) despite optimal long term antiplatelet therapy …
[How to manage the patients with hypoxic pulmonary hypertension?].
Lewczuk J, Ludwik B. Lewczuk J, et al. Pol Merkur Lekarski. 2005 Oct;19(112):567-70. Pol Merkur Lekarski. 2005. PMID: 16379328 Review. Polish.
In this article pathophysiological background to use systemic vasodilators in treatment of HPH are described, and hemodynamical and clinical results of short and long term trials are discussed. Authors explain lack of clinical benefits with currently used systematic vasodi …
In this article pathophysiological background to use systemic vasodilators in treatment of HPH are described, and hemodynamical and clinical …
21 results